

Minutes of the 84th Meeting
of the Member State Committee
(MSC-84)

Wednesday 13 December
to Thursday 14 December 2023

Summary Record of the Proceedings and Conclusions and action points

Chair's opening address

The Chair, Katinka van der Jagt, welcomed all participants to the 84th MSC meeting with onsite participation. The Chair mentioned a few highlights of the meeting, including SVHC identification, one compliance checks (under Dossier evaluation), the update of the CoRAP and the draft for the 12th Annex XIV recommendation. Three general topics in relation to dossier evaluation process were also indicated among the other interesting topics for this meeting.

Agenda point	
Conclusions / agreements / adoptions	Action requested after the meeting (by whom/by when)
Item 2 – Adoption of the Agenda	
The Agenda (MSC/A/84/2023) was adopted as modified at the meeting.	SECR to upload the adopted Agenda to Interact and the ECHA website as part of the MSC-84 minutes.
Item 3 – Declaration of specific interests to items on the Agenda	
No potential conflicts of interests were declared by the MSC Chair, any members, experts or advisers with any item on the agenda of MSC-84.	
Item 4 – Administrative issues	
<ul style="list-style-type: none"> Outlook for MSC-85 The Chair presented an outlook on the potential length of the MSC-85 (February 2024) meeting of 1 or possibly 1,5 days, normally starting on a Tuesday.	
Item 5 – Minutes of the MSC-83	
SECR informed the Committee that the minutes of MSC-83, adopted by MSC at that meeting, are published on Interact and on ECHA's website.	
Item 6 - Substance evaluation	
No items.	
Item 7 - Dossier evaluation - Discussion and seeking agreement on draft decisions (DDs) on compliance checks and testing proposals when amendments were proposed by MS-CA's	
Compliance checks	
CCH-197/2023 1,3,5-tris(2,3-dibromopropyl)-1,3,5-triazine-2,4,6(1H,3H,5H)-trione (EC No. 257-913-4)	
Session 1 & 2 (open & closed)	

A representative of the Registrant participated in the initial discussion. In absence of specific confidentiality concerns in the DD, an open session was held followed by discussion and voting in closed session.

ECHA Secretariat (SECR) introduced the proposal for amendments (PfAs):

1) Proposal for the Transgenic rodent somatic and germ cell gene mutation assays (TGR) requested in the decision:

a. Change the wording in section "10.3.5.2. Germ cells" of TGR from "may collect" to "must collect" the male germ cells (from the seminiferous tubules). This clarifies that the collection of male germ cells is a requirement, in case a TGR is the performed test to cover the information requirement for *in vivo* genotoxicity somatic cell testing.

2) Proposal to add a requirement to analyse the germ cells collected if any of the somatic tissues are positive for TGR.

SECR had modified the decision, in line with PfA 1.a before the meeting, but did not modify for PfA 2, awaiting discussion in the meeting.

The Registrant had submitted written comments on the PfAs and MSC duly considered them in its discussion. In the meeting the Registrant agreed with considerations of the decision from a toxicological view point.

In the meeting, the representative of the Registrant indicated its intention to downgrade the tonnage band of the substance. SECR pointed out that the Registrant had not informed ECHA about the tonnage downgrade before its intervention in the meeting.

SECR clarified that PfA 2 is not proposing to perform an additional TGR exclusively to analyse germ cells, but rather to analyse the germ cells, collected under request 10 of the decision, i.e., the TGR following the 28+28 days regime.

MSC members agreed to modify the draft decision as proposed in the PfAs, agreeing with PfA 1 and PfA 2.

The MSC reached unanimous agreement on the following ECHA draft decisions:

- CCH-197/2023
1,3,5-tris(2,3-dibromopropyl)-1,3,5-triazine-2,4,6(1H,3H,5H)-trione
(EC No. 257-913-4)

SECR to upload on Interact the agreed decision in the respective case agenda point.

7.3. General topics

1. Germ cell mutagenicity requests at Annex IX and X level

SECR introduced the current policy under dossier evaluation for requesting *in vivo* genotoxicity testing on germ cells, agreed by MSC in 2019-2020. The agreed line was to follow a two-decision approach:

- the first decision requests the *in vivo* genotoxicity test on somatic cells
- the second decision requests an adequate *in vivo* genotoxicity test on germ cells (only if there is a positive result in somatic cells *in vivo*)

At the time, no single available OECD TG allowed the conclusive analysis of both somatic and germ cells.

During MSC-83 a MSC member made a proposal to stop the two-decision approach for TGR requests, as:

- ECHA decisions, for TGR, already requests sampling of both somatic and germ cells at the same time and
- the revised OECD TG 488 allows concurrent analysis of both somatic and germ cells.

This proposal could potentially save time on concluding on the overall genotoxicity of substances. MSC agreed to continue the discussion at MSC-84 meeting.

<p>SECR provided to the MSC members background information to support their decision making:</p> <ul style="list-style-type: none"> - Potential proportion of cases where such change would have an impact. - SECR view on pros and cons of both approaches. - Implications to the dossier evaluation follow-up process. <p>Several MSC members voiced their support on a one-decision approach for TGR requests at Annex IX and X level. This would help to avoid delay between the conclusion of positive results for somatic cells and the analysis of the germ cells collected and stored, which potentially will shorten the time to decide on the adequate follow-up regarding further risk management options.</p>	
<p>The MSC agreed to modify the current approach for germ cell mutagenicity and follow a one-decision approach for decisions with a TGR request at annex IX and/or X. In detail, a decision at Annex IX and X level with a TGR request in somatic cells shall also include a conditional request to analyse the collected germ cells if the result of the TGR is positive in any of the analysed somatic cells.</p>	<p>SECR to apply the agreed change in policy in future decisions, both for compliance checks and testing proposal examinations.</p>
<p>2. OECD TG 234 requests at Annex VIII level</p>	
<p>SECR introduced a proposal for conditions to request OECD TG 234 study in compliance check decisions also at Annex VIII level, under Column 2 of Section 9.1. of Annex VIII.</p>	
<p>MSC members agreed with the relevance of SECR's proposal and agreed that the proposed approach would be applied in the future cases in which there is evidence on the potential endocrine disrupting properties of the registered substance. Additionally, an observer raised concerns regarding the inadequacy of OECD TG 234 for other uses, in particular regarding derivation of environmental quality indicators. Moreover, the difficulties in conducting the OECD TG 234 studies were remarked.</p>	<p>SECR to apply the agreed change in policy in future compliance check decisions</p>
<p>3. Effects meeting the classification criteria in testing proposals</p>	
<p>SECR introduced a suggestion for reviewing the approach in the testing proposal evaluation concerning certain endpoints in cases where the available data in the registration dossier shows effects that would meet the criteria for relevant classification and therefore fulfilling the relevant Column 2 adaptation criterium. SECR considers that in such situations the proposed study could therefore constitute unnecessary testing on vertebrate animals. According to SECR there may be grounds for rejecting such testing proposals based on a case-by-case examination when the data available in the registration dossier is manifestly sufficient to determine that the substance meets the criteria for the respective classification.</p> <p>The proposal was generally welcomed with some reservations that were clarified during the discussion. It was clarified that this approach would be used when effects show clear CMR properties resulting in classification as 1A/1B and that a formal decision-making process is involved when a testing proposal is rejected according to Article 40(3)(d) of REACH.</p>	
<p>It was agreed that the members and the observers can submit further reflections on the topic in writing to SECR by 26 January 2024 and later in the context of relevant draft decisions.</p>	<p>SECR to apply this approach in the relevant draft decisions.</p> <p>MSC members and StOs to submit further reflections on the topic to MSC FMB by 26 January 2024.</p>
<p>Item 8 - SVHC identification - Seeking agreement on Annex XV proposals for identification of SVHC</p>	

Bumetrizole (EC No. 223-445-4)

2-(2H-benzotriazol-2-yl)-4-(1,1,3,3-tetramethylbutyl)phenol (EC No. 221-573-5)

The dossier submitter (DS) expert from the German CA presented to MSC the draft Support Documents (SD) based on the Annex XV proposal for bumetrizole (UV-326) and 2-(2H-benzotriazol-2-yl)-4-(1,1,3,3-tetramethylbutyl)phenol (UV-329) and on the comments of the consultation of the interested parties. The substances were proposed for SVHC identification due to their vPvB properties under Art 57(e) of the REACH Regulation.

The justification for their SVHC identification was based on weight-of-evidence of the data available on the persistence and bioaccumulation.

The DS expert outlined the main comments received in the consultation on the Annex XV report, DS's responses to them and how they have been reflected in the SDs. The consultation had yielded both supporting and diverging views.

Regarding UV-326, an alternate member confirmed that their comments submitted in the consultation had been well responded in the revised SD, and further discussion is not needed.

Regarding UV-329, a member noted that the update of ECHA Guidance for PBT/vPvB assessment should be reflected in the SD. This editorial change will be done by the Secretariat. The member states who had submitted comments or proposed questions in the consultation confirmed that their comments had been sufficiently addressed in the SD. MSC considered issues raised in the consultation as resolved without further discussion. In addition, an expert to an observer stated that they disagree with the vB conclusion and revisited some of the industry comments submitted in the consultation. These included reliability of the OECD TG 305 study, validity of the *Hyalella Azteca* study, use of toxicokinetic data on UV-P for read-across with UV-329. DS made further clarifications in RCOM and SD for UV-329. MSC considered the comments being sufficiently addressed. EEB supported the identification of the substance as SVHC.

MSC unanimously agreed that Bumetrizole (UV-326) and 2-(2H-benzotriazol-2-yl)-4-(1,1,3,3-tetramethylbutyl)phenol (UV-329) are substances under Article 57 (e) of Regulation (EC) 1907/2006 (REACH), which are very persistent and very bioaccumulative (vPvB) in accordance with the criteria and provisions set out in Annex XIII of REACH.

Three SVHC cases had been agreed by MSC in written procedure and one SVHC case did not require MSC referral (see Appendix of the Final Agenda below).

SECR to upload the MSC agreements, the support documents and RCOMs on Interact in the respective agenda point and to publish them on the ECHA website.

SECR to add the newly identified SVHCs to the Candidate List (update foreseen on 23 January 2024).

Item 9 – ECHA's recommendations of priority substances to be included in Annex XIV and opinion of MSC

Presentation and discussion of 12th draft recommendation

SECR presented the updated prioritisation results and proposal for 12th draft recommendation, providing its general considerations on which substances and how many to recommend, with the aim of having a proportionate Annex XIV recommendation. More detailed assessments had been shared as meeting documents.

Since for some of the substances there are restriction development ongoing, SECR invited MSC to provide its view on the characteristic of activities towards restriction which would justify postponing the recommendation of a substance for authorisation.

In the following discussion MSC acknowledged the work carried out to come up with the draft recommendation and the considerations shared by SECR to discuss which restriction activities

would justify postponing the recommendation of a substance. The enhanced transparency was noted, however, several interventions pointed out that there are grey areas on when a certain planned restriction related activity is clear or confirmed enough to be taken into account. As regards the number of substances to be included in the draft recommendation, some members mentioned that the number of substances already recommended but not yet included in Annex XIV should not impact ECHA's recommendation.

SECR suggested to include Melamine, S-(tricyclo[5.2.1.0 2,6]deca-3-en-8(or 9)-yl) O-(isopropyl or isobutyl or 2-ethylhexyl) O-(isopropyl or isobutyl or 2-ethylhexyl) phosphorodithioate, Diphenyl(2,4,6-trimethylbenzoyl)phosphine oxide, Barium diboron tetraoxide. For Bis(2-ethylhexyl) tetrabromophthalate feedback was requested to help concluding if in view of MSC there is basis to postpone inclusion of that substance or not. Several speakers saw benefits in addition of more substances, and Bis(2-ethylhexyl) tetrabromophthalate in particular, in the situation where a restriction commitment or its impact is not clear, as in this case, and as there would still be an option to drop substances from the final recommendation if need be, following the consultation round. One member argued that it would be useful to have some flexibility in terms of what would be considered as sufficient basis to postpone recommendation of a given substance if not yet covered by an entry in the Restriction Registry of intentions (ROI).

As regards the Annex XIV entries SECR proposed not to assign precise Latest Application Dates (LADs) at this stage as information from the 3-months consultation is expected to provide useful information in this regard. No review periods nor exemptions were included to the draft Annex XIV entries. No comments were raised on this proposal.

As regards Dibutyl phthalate (EC No. 201-557-4) SECR reminded that since this substance now was identified by MSC as SVHC for additional property (ED for environment), the Annex XIV should be amended accordingly to take account of that. Therefore, there will be a separate consultation of interested parties and also opinion of MSC on this amendment recommendation will be needed.

<p>MSC took note of the draft recommendation which included four or possibly five substances and of which one was specifically raised for discussion. MSC requested for some further clarification as well as provided some feedback.</p>	<p>MSC to submit comments on the substances to be included in the draft recommendation by 5 January 2024. Comments on the general criteria were welcomed more for future purposes. SECR to finalise ECHA's draft 12th recommendation for publishing it for three-month consultation in February 2024.</p>
---	---

Item 10 – ECHA's draft update of the Community Rolling Action Plan and opinion of MSC

1) Appointment of Co-Rapporteur
Due to the change in the membership a new Co-Rapporteur needed to be appointed for the MSC opinion drafting on the draft CoRAP update.

<p>MSC appointed one of its members to become a Co-Rapporteur.</p>	<p>SECR to send the appointment letter to the newly nominated Co-Rapporteur.</p>
--	---

2) Introduction of the draft CoRAP update for 2024-2026 by SECR

SECR presented the draft Community Rolling Action Plan (CoRAP) update for 2024-2026 which had been referred to MSC on 30 November 2023. The draft CoRAP update for years 2024-2026 has a total of 28 substances for evaluation, 11 new CoRAP candidates and 17 substances that were already included in the CoRAP. One substance had been withdrawn from the previous list, and justification for its withdrawal was also made available to MSC. It was explained that each new substance has an accompanying justification document. The year of evaluation had been postponed for 11 entries on the list, mainly due to ongoing dossier evaluation.

<p>MSC took note of the draft CoRAP update for 2024-2026 and the changes and new substances that were added to it.</p>	<p>Rapporteur to provide the draft opinion of MSC on the draft CoRAP update by 30 January 2024 for adoption in MSC-85.</p>
--	---

Item 11 – MSC Manual of decisions (MoD)	
Update of the MSC MoD	
SECR thanked MSC for the feedback received following MSC-83 and introduced the modifications to the MoD that were included based on those. As a result, also a number of new entry suggestions to MSC’s MoD were presented for MSC’s review.	
MSC took note of the suggested modifications and new entries and proposed some further edits. MSC decided to update the MoD with the given modifications.	<p>SECR to finalise the MSC MoD for sharing it via MSC Interact by early January 2024.</p> <p>SECR to explore how the MSC MoD could be shared also with a broader audience (e.g. ECHA website).</p>
Item 12 – Any other business	
1. Updates on appeals and court cases of relevance to MSC	
SECR gave an overview of pending appeal and court cases and recent judgements on Evaluation and SVHC identification in both open and closed sessions.	
2. Suggestions from members	
2.1 Presentation of the FSDT survey results	
Following discussion at MSC-82 (item 12.5.c) and a brief update at MSC 83, two MSC members presented the results of a survey performed to gather feedback on the OECD TG 234 studies received, and the effectiveness of OECD TG 234 studies to identify substances as endocrine disruptors.	
The survey was addressed to Member States and covers substances assessed under REACH and Biocides regulations.	
The MSC member also presented a proposal for an informal working group on possible follow-up actions of the survey.	
MSC took note of the survey results and supported the proposal for an informal working group on possible follow-up actions.	FR to create a discussion document summarising the survey findings and proposals for follow-up actions in early 2024 to be discussed by the informal working group.
Item 13 – Adoption of summary record of the proceedings and conclusions and action points	
Table with summary record and conclusions and action points from MSC-84	
MSC adopted the Summary Record of the Proceedings and Conclusions and Action points at the plenary meeting.	SECR to upload the Summary Record of the Proceedings and Conclusions and Action points from MSC-84 on Interact by 18 December 2023 as well as ECHA website without undue delay.

II. List of attendees

<u>Members/Alternate members</u>	<u>ECHA staff</u>
ALMEIDA, Ines (PT)	AJAO, Charmaine
ATTIAS, Leonello (IT)	ALARANTA, Joonas
BARTHELEMY, Johanna (FR)	ANAGNOSTAKIS, Konstantinos
BAUMBUSCH, Angelika (NO)	BECKER, Falk
DE KNECHT, Johan (NL)	BROERE, William
DUDRA, Agnieszka (PL)	CALEY, Jane
FERNÁNDEZ SÁNCHEZ, Raquel (ES)	CAMPBELL, Pamela
FINDENEGG, Helene (DE)	CARTON DE TOURNAI, Laure-Anne
GRIZELJ, Romana (HR)	DE COEN, Wim
HJORTH, Rune (DK)	JUTILA, Arimatti
HUMAR JURIĆ, Tatjana (SI)	KARKOLA, Sampo
KULHÁNKOVÁ, Pavlína (CZ)	KENIGSWALD, Hugues
KUROVÁ, Martina (SK)	LE CURIEUX, Frank
LIADAKIS, Georgios (GR) (remote attendance)	LUOMA, Leena
MALKIEWICZ, Katarzyna (SE)	MESTRE, Diana
MATĪSA, Sandra (LV)	MULTASUO, Tiina
MIHALCEA UDREA, Mariana (RO)	RASENBERG, Mike
MURRAY, Brendan (IE)	RIBEIRO, Lucie
PALEOMILITOU, Maria (CY) (remote attendance)	RUOSS, Jurgen
RISSANEN, Eeva (FI)	VAHTERISTO, Liisa
SAKSA, Jana (EE)	VAN DER JAGT, Katinka
ŠPŪRIENĒ, Otilija (LT)	VIEIRA LISBOA, Duarte
STOCKER, Eva (AT)	WALKER, Lee
TARNÓCZAI, Tímea (HU) (remote attendance)	
TREZZI, Jean Pierre (LU) (remote attendance)	
VANDERSTEEN, Kelly (BE) (remote attendance)	
YORDANOV, Yordan (BG)	
<u>Observers</u>	
ARROYO, Jesus (Cefic)	
DROHMANN, Dieter (ORO)	
LENNQUIST, Anna (ChemSec)	
LOONEN, Helene (EEB)	
POCHAT, Julia (Eurogroup for Animals) (remote attendance)	
SCHENTEN, Julian (ClientEarth)	
SHIPTON, Kate (Cruelty Free Europe) (remote attendance)	
WAETERSCHOOT, Hugo (Eurometaux)	

Apologies

n/a

Proxies

PALEOMILITOU, Maria (CY) to LIADAKIS, Georgios (EL), from 15.30 onwards on 13 and 14 December

MALKIEWICZ, Katarzyna (SE) to DE KNECHT, Joop (NL) on 14 December pm if needed

Experts and advisers to MSC members

MUEHLEGGER, Simone (AT) – (Expert to STOCKER, Eva) (remote attendance)
REHRL, Anna-Lena (AT) – (Expert to STOCKER, Eva) (remote attendance)
DOBRAK–VAN BERLO, Agnieszka (BE) – (Expert to VANDERSTEEN, Kelly) (remote attendance)
FILIPOVA, Hristina (BG) – (Expert to YORDANOV Yordan)
KOZMIKOVA, Jana (CZ) – (Expert to KULHANKOVA, Pavlina)
ACKERMANN, Juliane (DE) – (Expert to FINDENEGG, Helene)
BÖHNHARDT, Anna (DE) – (Expert to FINDENEGG, Helene) (remote attendance)
CLAßEN, Daniela (DE) – (Expert to FINDENEGG, Helene) (remote attendance)
GUENDEL, Ulrike (DE) – (Expert to FINDENEGG, Helene) (remote attendance)
JOEHNCKE, Ulrich (DE) – (Expert to FINDENEGG, Helene) (remote attendance)
NAGEL, Gregor (DE) – (Expert to FINDENEGG, Helene) (remote attendance)
ROSENTHAL, Esther (DE) – (Expert to FINDENEGG, Helene) (remote attendance)
UNKELBACH, Christian (DE) – Expert to FINDENEGG, Helene) (remote attendance)
WÄCHTER, Tobias (DE) – (Expert to FINDENEGG, Helene) (remote attendance)
BOLWIG, Asger (DK) – (Expert to HJORTH, Rune)
EINOLA, Juha (FI) - (Expert to RISSANEN, Eeva)
KAARTINEN, Tomi (FI) – (Expert to RISSANEN, Eeva) (remote attendance)
LAAKKONEN, Anita (FI) - (Expert to RISSANEN, Eeva)
BURGA, Karen (FR) – (Expert to BARTHELEMY-BERNERON, Johanna)
ZELJEZIC, Davor (HR) - (Expert to GRIZELJ, Romana)
BRODERICK, Mike (IE) – (Expert to MURRAY Brendan)
ALIVERNINI, Silvia (IT) – (Expert to ATTIAS, Leonello) (remote attendance)
CATONE, Tiziana (IT) - (Expert to ATTIAS, Leonello)
BALCIUNIENE, Jurgita (LT) - (Expert to ŠPŪRIENĖ, Otilija)
VERBRUGGEN, Eric (NL) – (Expert to DE KNECHT Joop) (remote attendance)
REIERSON, Linda (NO) –(Expert to BAUMBUSCH, Angelika)
CIESLA, Jacek (PL) - (Expert to DUDRA, Agnieszka)
MENDONCA, Elsa (PT) – (Expert to ALMEIDA Ines) (remote attendance)
COPOIU, Oana (RO) - (Expert to MIHALCEA UDREA, Mariana)
ANDERSSON Lars (SE) - (Expert to MALKIEWICZ, Katarzyna) (remote attendance)
ARABI, Azadeh (SE) – (Expert to MALKIEWICZ, Katarzyna)
SÄLL, Liselotte (SE) – (Expert to MALKIEWICZ, Katarzyna) (remote attendance)

Occasional Stakeholder Experts

N/A

Experts to regular observers

SCHMITT, Christian (Expert for Cefic Observer) for AP 8.1. SVHC identification for UV-326 & UV-329

Case owners

The case owner representative was attending under the Agenda Item 7.1 for CCH-197/2023 - 1,3,5-tris(2,3-dibromopropyl)-1,3,5-triazine-2,4,6(1H,3H,5H)-trione (EC No. 257-913-4)

Final Agenda Draft Agenda 84th meeting of the Member State Committee

13-14 December 2023

13 December 2023: starts at 10:00 am

14 December 2023: ends at 6:00 pm

Item 1 – Welcome and Apologies

Item 2 – Adoption of the Agenda

MSC/A/084/2023
For adoption

Item 3 – Declaration of specific interests to items on the Agenda

Item 4 – Administrative issues

- Outlook for MSC-85

For information

Item 5 – Minutes of the MSC-83

- [Adopted minutes of MSC-83](#)

For information

Item 6 – Substance evaluation

1. Introduction to and preliminary discussion on draft decisions on substance evaluation when amendments were proposed by MS-CA's/ECHA (*Session 1, open session*):

MSC code	Substance name ¹	EC/List No.
----------	-----------------------------	-------------

No cases

[For discussion]

2. Seeking agreement on draft decisions when amendments were proposed by MS-CA's/ECHA (*Session 2, closed*)

No cases

[For agreement]

3. General topics

[For information]

Item 7 – Dossier evaluation

Closed session for 7.2 and partly for 7.3

¹ List of cases agreed in MSC Written Procedure is available in the Appendix of this draft agenda.

1. Introduction to and preliminary discussion on draft decisions on compliance checks and testing proposals when amendments were proposed by MS-CA's (*Session 1, open session*)

ECHA/MSC-84/2023/011
For information

For discussion followed by agreement seeking under 7.2:

Compliance checks¹

MSC code	Substance name	EC No. / Documents
CCH-197/2023	1,3,5-tris(2,3-dibromopropyl)-1,3,5-triazine-2,4,6(1H,3H,5H)-trione	257-913-4 ECHA/MSC-84/2023/009-10

Testing proposal examinations

No cases

For information and discussion

2. Seeking agreement on draft decisions on compliance checks and testing proposal examinations when amendments were proposed by MS-CA's (*Session 2, closed*)

Case as listed under 7.1

For agreement

3. General topics

1. Germ cell mutagenicity requests at Annex IX and X level (*Partly closed session*)

For discussion

2. OECD TG 234 requests at Annex VIII level (*Partly closed session*)

For discussion

3. Effects meeting the classification criteria in testing proposals (*Open session*)

For discussion

Item 8 – SVHC identification - Seeking agreement on Annex XV proposals for identification of SVHC

1. Seeking agreement on Annex XV proposals for identification of SVHC

Substance name ¹	EC/List No.	Documents
Bumetrizole	223-445-4	ECHA/MSC-84/2023/012&014
2-(2H-benzotriazol-2-yl)-4-(1,1,3,3-tetramethylbutyl)phenol	221-573-5	ECHA/MSC-84/2023/013&015

For agreement

Item 9 – ECHA's recommendations of priority substances to be included in Annex XIV and opinion of MSC

Presentation and discussion of 12th draft recommendation

ECHA/MSC-84/2023/005-6
For discussion

Item 10 – ECHA’s draft update of the Community Rolling Action Plan and opinion of MSC

- Appointment of Co-Rapporteur for drafting of the MSC opinion on draft annual CoRAP update
For decision
- Introduction of the draft CoRAP update for 2024-2026 by SECR

ECHA/MSC-84/2023/001

For information

Item 11 – MSC Manual of Decisions (MoD)

Update of the MSC MoD

ECHA/MSC-84/2023/007-8

For discussion and decision

Item 12 – Any other business

Item 12.1 partly closed session

1. Updates on appeals and court cases of relevance to MSC

(Partly closed session)

For information

2. Suggestions from members:

- 2.1 Presentation of the FSDT survey results

For information

Item 13 – Adoption of summary record of the proceedings and conclusions and action points

- Table with summary record and conclusions and action points from MSC-84

For adoption

INFORMATION DOCUMENTS

Information documents are not allocated a specific agenda time but the documents are available on Interact MSC Meetings module before the meeting. Based on the listed documents and the meeting agenda, if any MSC member considers that information documents may merit a discussion under any agenda point, they should inform MSC Secretariat.

- Written procedure report on seeking agreement on draft decisions on substance evaluation (For members only)
- Written procedure report on seeking agreement on draft decisions on dossier evaluation (For members only)
- Written procedure report on seeking agreement on identification of SVHCs

APPENDIX to the MSC-84 agenda:

List of cases agreed by MSC in written procedure in advance of the MSC-84 meeting:

Substance evaluation

MSC code	Substance name	EC/List No.
SEV-FR-005/2017	Reaction Mass of 1-(1,2,3,4,5,6,7,8-octahydro-2,3,8,8-tetramethyl-2-naphthyl)ethan-1-one and 1-(1,2,3,4,6,7,8,8a-octahydro-2,3,8,8-tetramethyl-2-naphthyl)ethan-1-one and 1-(1,2,3,5,6,7,8,8a-octahydro-2,3,8,8-tetramethyl-2-naphthyl)ethan-1-one (OTNE)	915-730-3

Dossier evaluation

Compliance checks (CCH)

MSC code	Substance name	EC/List No.
CCH-201/2023	Multi-Walled Carbon Nanotubes (MWCNT), synthetic graphite in tubular shape	936-414-1

SVHC identification²

Substance name	EC No.	CAS No.
2,4,6-tri-tert-butylphenol (2,4,6-TTBP)	211-989-5	732-26-3
Dibutyl phthalate	201-557-4	84-74-2
Oligomerisation and alkylation reaction products of 2-phenylpropene and phenol (OAPP)	700-960-7	-

² 2-(dimethylamino)-2-[(4-methylphenyl)methyl]-1-[4-(morpholin-4-yl)phenyl]butan-1-one (EC No. 438-340-0) was not referred to the MSC and will be added directly to the Candidate list.